OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in ...

Investing.com -- OSR Holdings Inc (NASDAQ:OSRH) stock surged 30.5% on Friday after the company announced its subsidiary Vaximm AG had entered a non-binding term sheet with BCM Europe AG to explore a ...

OSR Holdings (OSRH) announced that Vaximm AG, an OSR company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life ...

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and ...

The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...

Researchers at UMC Utrecht developed two first-in-class antibodies that block FcγRI, offering new options to reduce ...

OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

Barré syndrome market is poised for substantial growth, fueled by advancements in treatment options, including intravenous immunoglobulin (IVIg), plasmapheresis, and emerging immunotherapies.

Over 60% of human infectious diseases come from animals. Learn what zoonotic diseases are, how they are transmitted, and why animal health is human health.

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other ...

Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.